Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (3696)	5/8/2001 10:45:33 AM
From: Harold Engstrom	Respond to of 52153

The dosage is indeed different. I would expect the stock to slowly sell off for a while - something like what Chiron did when Avonex hit the market. Amevive should do well, but it will have to do well. Biogen has grown significantly over the past 6 years and now has significant infrastructure to support - if they lose $100MM in revenues, it will come right out of EBIT. Biogen has been terribly slow to make deals to shore up its pipeline. What we saw at Vertex with respect to the company rounding out its drug discovery methodologies and partnering with other pharmaceuticals is not happening at Biogen. Would like Biogen to use its infrastructure and solid science to leverage the business of other smaller biotechs and that of pharmaceuticals that are weak in biotech.